Alcohol potentiates hepatitis C virus replicon expression.
Alcohol consumption accelerates liver damage and diminishes the anti-hepatitis C virus (HCV) effect of interferon alfa (IFN-alpha) in patients with HCV infection. It is unknown, however, whether alcohol enhances HCV replication and promotes HCV disease progression. The availability of the HCV replicon containing hepatic cells has provided a unique opportunity to investigate the interaction between alcohol and HCV replicon expression. We determined whether alcohol enhances HCV RNA expression in the replicon containing hepatic cells. Alcohol, in a concentration-dependent fashion, significantly increased HCV replicon expression. Alcohol also compromised the anti-HCV effect of IFN-alpha. Investigation of the mechanism(s) responsible for the alcohol action on HCV replicon indicated that alcohol activated nuclear factor kappaB (NF-kappaB) promoter. Caffeic acid phenethyl ester (CAPE), a specific inhibitor of the activation of NF-kappaB, abolished alcohol-induced HCV RNA expression. In addition, naltrexone, an opiate receptor antagonist, abrogated the enhancing effect of alcohol on HCV replicon expression. In conclusion, alcohol, probably through the activation of NF-kappaB and the endogenous opioid system, enhances HCV replicon expression and compromises the anti-HCV effect of IFN-alpha. Thus, alcohol may play an important role in vivo as a cofactor in HCV disease progression and compromise IFN-alpha-based therapy against HCV infection.
Zhang
Ting
T
Division of Allergy and Immunology, Joseph Stokes Jr. Research Institute at The Children's Hospital of Philadelphia, Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
Li
Yuan
Y
Lai
Jian-Ping
JP
Douglas
Steven D
SD
Metzger
David S
DS
O'Brien
Charles P
CP
Ho
Wen-Zhe
WZ
D000931:Antidotes / Q000494:pharmacology; D000998:Antiviral Agents / Q000494:pharmacology; D002478:Cells, Cultured; D002492:Central Nervous System Depressants / Q000494:pharmacology*; D003484:Cyanamide / Q000494:pharmacology; D004347:Drug Interactions; D000431:Ethanol / Q000494:pharmacology*; D000077604:Fomepizole; D016174:Hepacivirus / Q000187:drug effects / Q000235:genetics / Q000254:growth & development*; D019698:Hepatitis C, Chronic / Q000821:virology*; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology; D016328:NF-kappa B / Q000378:metabolism; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D012367:RNA, Viral / Q000378:metabolism; D012093:Replicon / Q000187:drug effects* / Q000502:physiology
D000931:Antidotes; D000998:Antiviral Agents; D002492:Central Nervous System Depressants; D016328:NF-kappa B; D009292:Narcotic Antagonists; D011720:Pyrazoles; D012367:RNA, Viral; D000431:Ethanol; D003484:Cyanamide; D009271:Naltrexone; D007371:Interferon-gamma; D000077604:Fomepizole